Parkinson’s disease develops when nerve cells in a specific part of the brain gradually die off, cutting the supply of a chemical messenger called dopamine that controls movement. There is no single cause. For most people, Parkinson’s results from a combination of genetic vulnerability, environmental exposures, and aging, with the vast majority of cases appearing after age 50 and peaking between ages 65 and 84.
What Happens Inside the Brain
The core problem in Parkinson’s is the loss of dopamine-producing neurons in a brain region called the substantia nigra. These neurons help coordinate smooth, intentional movement. As they die, dopamine levels drop, and the hallmark symptoms emerge: tremor, stiffness, slowness, and balance problems.
The damage traces back to a small protein called alpha-synuclein. In a healthy brain, this protein folds into a normal shape and does its job at nerve endings. In Parkinson’s, alpha-synuclein misfolds, clumping into sticky clusters that recruit more normal proteins to join them. These clumps, called Lewy bodies, poison neurons in several ways at once. They disrupt mitochondria (the tiny power plants inside cells), interfere with the cell’s waste-disposal system, and throw off calcium levels. The result is a slow, progressive wave of cell death that can unfold over years or even decades before symptoms become noticeable.
Genetics: A Factor, Not a Fate
Only about 15 to 20% of people with Parkinson’s have a clear family history of the disease. Researchers have identified mutations in at least five key genes linked to familial Parkinson’s, but carrying one of these mutations doesn’t guarantee you’ll develop it.
The most commonly discussed gene is LRRK2, where a single mutation (known as G2019S) has been found in families and sporadic cases worldwide. Another important gene is SNCA, which provides the blueprint for alpha-synuclein itself. People who carry extra copies of this gene produce more alpha-synuclein protein, increasing the chance of toxic clumping. Mutations in three other genes, PARK2, PINK1, and DJ-1, tend to cause earlier-onset Parkinson’s by impairing the cell’s ability to clean up damaged mitochondria.
For the remaining 80 to 85% of cases, genetics still plays a role, just a subtler one. Dozens of common gene variants each nudge risk up or down by small amounts. These interact with environmental factors and aging in ways researchers are still mapping out.
Environmental Exposures That Raise Risk
Certain pesticides and industrial chemicals are among the strongest environmental risk factors identified so far. Two stand out in research: rotenone, a pesticide that directly disrupts mitochondrial energy production in nerve cells, and paraquat, an herbicide that floods cells with damaging molecules called reactive oxygen species. Both have been associated with roughly 2.5 times the risk of Parkinson’s compared to people who were never exposed. Paraquat has also been shown in lab studies to trigger alpha-synuclein clumping and selectively damage the same dopamine-producing neurons lost in Parkinson’s.
The mechanism behind rotenone mirrors what happens with MPTP, a synthetic compound famously known to cause rapid-onset parkinsonism in drug users in the 1980s. Both shut down the same energy-production step inside mitochondria, starving neurons of fuel and generating toxic byproducts. This connection between pesticide exposure and the disease partly explains why men, who have historically held more agricultural jobs, are diagnosed more often. Globally, men are about 1.2 times more likely to develop Parkinson’s than women, though that gap appears to be narrowing over recent decades.
Head Injuries and Long-Term Risk
Traumatic brain injury is an established risk factor, particularly in middle-aged and older adults. A large study of trauma patients age 55 and older found that those who sustained a brain injury had a 44% higher risk of developing Parkinson’s over the following five to seven years compared to people who experienced other types of trauma, like a broken bone.
The risk scales with severity and frequency. A mild brain injury raised the risk by 24%, while moderate or severe injuries raised it by 50%. People who suffered more than one brain injury had an 87% increased risk compared to those with non-brain trauma. This dose-response pattern held regardless of whether the injury came from a fall or another cause.
The Gut-Brain Connection
One of the more striking findings in recent Parkinson’s research is that the disease may sometimes begin outside the brain entirely. Misfolded alpha-synuclein has been detected in the nervous system lining the gut before any motor symptoms appear. Evidence now supports the idea that these toxic protein clumps can travel from the gut to the brain along the vagus nerve, a long nerve connecting the digestive tract to the brainstem.
Changes in gut bacteria appear to play a role in this process. People with Parkinson’s consistently show different gut microbiome profiles than healthy individuals. Researchers refer to this as the “gut-first” hypothesis, and while it likely doesn’t explain every case, it helps account for why digestive problems like constipation often appear years before tremor or slowness.
Early Warning Signs That Precede Diagnosis
Parkinson’s has a long pre-motor phase where non-motor symptoms are already present but easily overlooked. Two of the most reliable early markers are loss of smell and a sleep disorder called REM sleep behavior disorder.
Loss of smell affects more than 90% of people who eventually receive a Parkinson’s diagnosis, and it can appear 10 to 20 years before motor symptoms. The olfactory bulb, which processes smell signals, is one of the first brain areas where Lewy bodies accumulate. REM sleep behavior disorder, a condition where people physically act out their dreams because the normal muscle paralysis of deep sleep is absent, shows up in nearly half of Parkinson’s patients. It is now considered a prodromal stage of the disease, sometimes preceding diagnosis by decades.
Neither symptom on its own means Parkinson’s is inevitable. Loss of smell is common in the general population, affecting about 20% of people for various reasons. But when these symptoms appear together, or alongside constipation, depression, or anxiety, the pattern becomes more significant.
Age, Sex, and Protective Factors
Age is the single strongest risk factor. Prevalence rises sharply after 50, with the highest number of new cases occurring between 65 and 84. The peak in total cases hits the 80 to 89 age group for both men and women. This isn’t simply because older people have had more time to be exposed to toxins. Aging itself degrades mitochondrial function, weakens cellular repair mechanisms, and reduces the brain’s ability to clear misfolded proteins.
On the protective side, caffeine has one of the most consistent associations with reduced risk. Epidemiological studies show a dose-dependent relationship: the more caffeine a person regularly consumes, the lower their risk tends to be. Animal studies support this, showing caffeine has direct neuroprotective effects on dopamine-producing neurons. Regular physical exercise also appears protective, though the specific type or intensity needed to meaningfully lower risk is still being refined. Some research suggests that the Mediterranean diet and certain lifestyle patterns common in different populations may contribute to the geographic variation in Parkinson’s rates.
Interestingly, smoking has repeatedly been associated with lower Parkinson’s risk in population studies, though the health trade-offs make it an obviously poor strategy. The nicotine connection has prompted research into whether nicotine-like compounds could offer neuroprotection without the harms of tobacco.